The pathway enrichment analysis highlighted that MEHP predominantly affected pathways including non-alcoholic fatty liver disease (NAFLD), oxidative phosphorylation (OXPHOS), thermogenesis, cholesterol metabolism, and PPAR signaling (Figure 1E). This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.